Effects of Akatinol Memantine on Gait Disturbances at the Developed Stages of Parkinson’s Disease

Miliukhina, Irina; Gracheva, E.

doi:10.1007/s11055-021-01087-1

Cited by 1 publication

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…107 , 108 Anti‐excitotoxicity drugs such as memantine block glutamate receptors are tested for reducing involuntary movements (dyskinesias) in PD. 109 Anti‐inflammatory therapies such as Omega‐3 fatty acid Docosahexaenoic acid are tested for reducing neuroinflammation and consequent improvement in dyskinesia. Small molecule drugs targeting regeneration use neurotrophic factors to protect and repair neurons.…”

Section: Parkinson's Therapies In the Clinicmentioning

confidence: 99%

“…107,108 Anti-excitotoxicity drugs such as memantine block glutamate receptors are tested for reducing involuntary movements (dyskinesias) in PD. 109 a key goal of these therapies, with many trials employing stem cells which can differentiate into dopaminergic neurons. A significant proportion of Regeneration therapies also test the utility of neurotrophic factors such as GDNF and neurturin to protect dopaminergic neuron end terminals.…”

Section: Administration Routementioning

confidence: 99%

“…Anti‐apoptotic therapies such as TCH346 are tested for their efficacy in delaying loss of dopaminergic neurons 107,108 . Anti‐excitotoxicity drugs such as memantine block glutamate receptors are tested for reducing involuntary movements (dyskinesias) in PD 109 . Anti‐inflammatory therapies such as Omega‐3 fatty acid Docosahexaenoic acid are tested for reducing neuroinflammation and consequent improvement in dyskinesia.…”

Section: Parkinson's Therapies In the Clinicmentioning

confidence: 99%

See 2 more Smart Citations

Alzheimer's and Parkinson's disease therapies in the clinic

Chopade

Zhao

et al. 2022

Bioengineering & Transla Med

View full text Add to dashboard Cite

Alzheimer's disease (AD) and Parkinson's disease (PD) are the most prevalent neurodegenerative diseases, affecting millions and costing billions each year in the United States alone. Despite tremendous progress in developing therapeutics that manage the symptoms of these two diseases, the scientific community has yet to develop a treatment that effectively slows down, inhibits, or cures neurodegeneration. To gain a better understanding of the current therapeutic frontier for the treatment of AD and PD, we provide a review on past and present therapeutic strategies for these two major neurodegenerative disorders in the clinical trial process. We briefly recap currently US Food and Drug Administration‐approved therapies, and then explore trends in clinical trials across the variables of therapy mechanism of disease intervention, administration route, use of delivery vehicle, and outcome measures, across the clinical phases over time for “Drug” and “Biologic” therapeutics. We then present the success rate of past clinical trials and analyze the intersections in therapeutic approaches for AD and PD, revealing the shift in clinical trials away from therapies targeting neurotransmitter systems that provide symptomatic relief, and towards anti‐aggregation, anti‐inflammatory, anti‐oxidant, and regeneration strategies that aim to inhibit the root causes of disease progression. We also highlight the evolving distribution of the types of “Biologic” therapies investigated, and the slowly increasing yet still severe under‐utilization of delivery vehicles for AD and PD therapeutics. We then briefly discuss novel preclinical strategies for treating AD and PD. Overall, this review aims to provide a succinct overview of the clinical landscape of AD and PD therapies to better understand the field's therapeutic strategy in the past and the field's evolution in approach to the present, to better inform how to effectively treat AD and PD in the future.

show abstract

Section: Parkinson's Therapies In the Clinicmentioning

confidence: 99%

Section: Administration Routementioning

confidence: 99%